UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
__________________________________
FORM 6-K
__________________________________
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 under
the Securities Exchange Act of 1934
For the quarterly period ended September 30, 2024
Commission File Number 001-38332
__________________________________
QIAGEN N.V.
(Translation of registrant’s name into English)
__________________________________
Hulsterweg 82
5912 PL Venlo
The Netherlands
(Address of principal executive office)
__________________________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ý Form 40-F o
QIAGEN N.V.
Form 6-K
TABLE OF CONTENTS
| | | | | |
| |
| Item | Page |
| Other Information | |
| Signatures | |
| Exhibit Index | |
OTHER INFORMATION
For the three and nine months ended September 30, 2024, QIAGEN N.V. prepared its quarterly report under United States generally accepted accounting principles (U.S. GAAP). This quarterly report is furnished herewith as Exhibit 99.1 and incorporated by reference herein.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | | | | | | | |
| | |
| QIAGEN N.V. | |
| |
| By: | /s/ Roland Sackers |
| | Roland Sackers |
| | Chief Financial Officer |
Date: November 7, 2024
EXHIBIT INDEX
| | | | | | | | |
| | |
Exhibit No. | | Exhibit |
| | U.S. GAAP Quarterly Report for the Period Ended September 30, 2024 |
